← Back to Home

Seeking a Breakthrough Through Cerebrospinal Fluid Flow: eShunt Cleared for Study in Early Alzheimer’s Disease

CereVasc will investigate whether directing cerebrospinal fluid into veins can help clear harmful substances associated with the disease. The FDA’s clearance is for clinical research; whether the device can improve cognition or slow disease progression remains unanswered.

By SURL BioNews

Research into Alzheimer’s treatment is bringing a question into clinical study: can changing the flow of cerebrospinal fluid help the brain clear harmful substances associated with the disease? CereVasc announced on October 29 that the U.S. Food and Drug Administration (FDA) had approved its investigational device exemption (IDE) application, allowing the eShunt System to be evaluated in patients with early symptomatic Alzheimer’s disease.

The device is designed to divert cerebrospinal fluid into the venous system through a shunt implanted using a minimally invasive endovascular technique. Cerebrospinal fluid surrounds the brain and spinal cord and also helps transport and clear substances; the company hopes to investigate whether increasing the circulation and renewal of this fluid can support the brain’s existing clearance processes. This remains a mechanistic hypothesis that requires validation and cannot directly be taken to imply improved memory or slower disease progression.

The significance of this regulatory development is that it allows the hypothesis to be tested in human research. An IDE is not marketing authorization, nor does it mean the FDA has determined that the device has a therapeutic effect. In announcements on its website and distributed through PR Newswire, CereVasc explicitly stated that eShunt has not been approved for commercial sale by the FDA or any other regulatory authority, and that its safety and effectiveness remain unestablished.

eShunt also has another clinical development pathway. According to the company’s announcement and reporting by the specialist publication NeuroNews International, STRIDE, a pivotal randomized controlled trial for normal pressure hydrocephalus, recently completed enrollment. However, completing enrollment does not mean the trial has succeeded; experience accumulated in hydrocephalus also cannot directly establish that the device is effective for Alzheimer’s disease. Each disease requires its own clinical evidence.

This announcement provided no study results in patients with Alzheimer’s disease and did not specify the planned enrollment, control design, primary endpoints, or follow-up duration. Subsequent reporting by Philenews likewise noted that there is currently no evidence that the device can effectively clear the relevant substances in patients with Alzheimer’s disease or provide cognitive benefits. What can be confirmed at this stage is that the research has been authorized, rather than that efficacy has been demonstrated.

Next, clinical research must answer not only whether fluid flow changes, but also whether that change can safely translate into benefits that patients can perceive. Even if changes in clearance-related measures are observed in the future, their relationship to cognition, daily functioning, and disease progression will still require further assessment. This research authorization opens a new path along which evidence must be built step by step.

References

  1. CereVasc
  2. CereVasc, Inc. via PR Newswire
  3. NeuroNews International
  4. Philenews